Psychedelic Research Chemicals or RC Chems are new synthetic substances which are structurally similar to the original drug, while being functional analogs. Data on their effects limited due as they’re fairly new and do not have a lot of human consumption history.

Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Description

6-APDB Also known as:

  • 1-(2,3-Dihydro-1-benzofuran-6-yl)-2-propanamin[German][ACD/IUPAC Name]
  • 1-(2,3-Dihydro-1-benzofuran-6-yl)-2-propanamine[ACD/IUPAC Name]
  • 1-(2,3-Dihydro-1-benzofuran-6-yl)-2-propanamine[French][ACD/IUPAC Name]
  • 1-(2,3-Dihydro-1-benzofuran-6-yl)propan-2-amine
  • 6-(2-Aminopropyl)-2,3-dihydrobenzofuran
  • 6-Benzofuranethanamine, 2,3-dihydro-α-methyl-[ACD/Index Name]
  • 1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine (6-apdb)
  • 1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine
  • 2-(2,3-Dihydro-benzofuran-6-yl)-1-methyl-ethylamine
  • 2,3-Dihydro-α-methyl-6-Benzofuranethanamine
  • 6-(2-amineopropyl) -2,3-dihydrobenzofurane[ACD/IUPAC Name]
  • 6-(2-aminopropyl)-2,3-dihydrobenzo[b]furan
  • 6-APDB
  • 6-Benzofuranethanamine,2,3-dihydro-a-methyl-
  • 6-Nprop-dbf
  • PI-45417

A stimulant and entactogen related to MDMA and an analogue of MDA. Reported as being fairly psychedlic at higher doses. It is a triple monoamine reuptake inhibitor. Potent full agonist of serotonin 2B receptors.

Summary

It is a closely related synthetic analogue of MDA and 6-APB and broadly shares the characteristics of serotonin-selective triple monoamine releasers and reuptake inhibitors associated with other entactogenic or empathogenic compounds. 6-APDB was first synthesized and studied along with 5-APDB in 1993 by David E. Nichols as a potential non-neurotoxic alternative to MDMA.

It did not come into popular recreational use until over a decade later, where it briefly entered the rave scene and global research chemicals market, in particular the “legal highs” market in the U. K. , before its sale and import were subsequently banned.

Because 6-APDB and other substituted benzofurans have not been explicitly outlawed in some countries, they are often technically legal, contributing to their popularity as a substitute or replacement for serotonergic entactogens like MDMA or MDA, and are typically distributed through the online research chemicals grey market.

Chemistry

Molecules of this class contain a phenethylamine core bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. 6-APDB does not contain a methyl substitution on RN, a motif which it shares with MDA.

It is an analogue of MDA where the heterocyclic 4-position oxygen from the 3,4-methylenedioxy ring has been replaced with a methylene bridge.

6-APDB shares this furan ring with 5-APDB, 5-MAPDB and 6-MAPDB.

Common Name6-(2-Aminopropyl)-2,3-dihydrobenzofuran
Systematic name6-(2-Aminopropyl)-2,3-dihydrobenzofuran
FormulaC_{11}H_{15}NO
SMILESCC(Cc1ccc2c(c1)OCC2)N
Std. InChiInChI=1S/C11H15NO/c1-8(12)6-9-2-3-10-4-5-13-11(10)7-9/h2-3,7-8H,4-6,12H2,1H3
Std. InChiKeyVRNGXHJGMCJRSQ-UHFFFAOYSA-N
Avg. Mass177.2429 Da
Molecular Weight177.2429
Monoisotopic Mass177.115356 Da
Nominal Mass177
ChemSpider ID167141

Become an Exclusive Member For Free

Become a member now, sign up, and get free updates, news articles, and the latest happenings in the Psychedelic World.

Dose Chart

Oral
Threshold25-30mg
Low30-40mg
Medium40-75mg
Heavy75-100+mg

Duration Chart

6-APDB Duration Data
Onset60-90 minutes
Duration7-9 hours
After-effectsSome

Interactions

Caution

  1. Mushrooms
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  2. LSD
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  3. DMT
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  4. Mescaline
    • The focus and anxiety caused by stimulants is magnified by psychedelics and results in an increased risk of thought loops
  5. 2C-x
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally uneccessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  6. Cannabis
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  7. Ketamine
    • No unexpected interactions, though likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
  8. MXE
    • Risk of tachycardia, hypertension, and manic states
  9. Cocaine
    • This combination of stimulants will increase strain on the heart. It is not generally worth it as cocaine has a mild blocking effect on dopamine releasers like amphetamine
  10. Caffeine
    • This combination of stimulants is not generally necessary and may increase strain on the heart, as well as potentially causing anxiety and greater physical discomfort.
  11. Alcohol
    • Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less. Extended release formulations may severely impede sleep, further worsening the hangover.
  12. GHB/GBL
    • Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  13. Opioids
    • Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.

Dangerous

  1. DOx
    • The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
  2. NBOMes
    • Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and in extreme cases heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
  3. 2C-T-x
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences. In extreme cases, they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
  4. 5-MeO-xxT
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  5. DXM
    • Both substances raise heart rate, in extreme cases, panic attacks caused by these drugs have led to more serious heart issues.
  6. PCP
    • This combination can easily lead to hypermanic states

Low Synergy

  1. Benzodiazepines
    • Both can dull each other's effects, so if one wears off before the other it's possible to overdose due to the lack of counteraction

No Synergy

  1. SSRIs

High Synergy

  1. N2O
  2. MDMA
    • Amphetamines increase the neurotoxic effects of MDMA

Legal Status

Sources

References

  1. "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine"|https://www.ncbi.nlm.nih.gov/pubmed/8246240
  2. Effects of 6-APDB on the release of monoamines from rat brain slices https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582025/
  3. New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140
  4. Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full
  5. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805
  6. Drug-induced hyperthermia | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.1993.tb07423.x/abstract;jsessionid=FC30A9B157A2BAFC81048D8595714565.f02t03
  7. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9634574
  8. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population | http://jop.sagepub.com/content/20/3/400
  9. Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full
  10. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805
  11. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
  12. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  13. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  14. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 18, 2019.
  15. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 18, 2019.
  16. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 18, 2019.
  17. http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
  18. http://www.legislation.gov.uk/uksi/2014/1106/contents/made

Information made possible with:

  1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
  2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
  3. PubChem National Center for Bio Informatics
  4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
  5. Wikipedia

Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

Data is constantly updated so please check back later to see if there is any more available information on this substance.